Renal function and the rate of disappearance of methotrexate from serum
- PMID: 1233246
- DOI: 10.1007/BF00562319
Renal function and the rate of disappearance of methotrexate from serum
Abstract
The disappearance of methotrexate (MTX) from serum was studied using H3-MTX. The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min. The corresponding apparent volume of distribution, V, obtained by extrapolation tended to decrease at lower levels of renal function. The total clearance of MTX calculated in this period varied linearly with creatinine clearance. In patients with normal serum creatinine concentration, the half-life increased with advancing age, which reflects the concurrent age-dependent decrease in creatinine production and renal function. This illustrates the need for knowledge of renal function, not based solely on serum creatinine concentration, in patients treated with methotrexate or other drugs eliminated by the kidneys. In 9 patients the results were not affected by treatment with diuretics (furosemide, hydroflumethiazide). In four patients serum MTX concentration was measured for up to 24-72 hours. An increasing half-life of MTX with time was found, suggesting that the elimination kinetics of the drug would be most adequately described by a multi-compartment model.
Similar articles
-
High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).Cancer Chemother Pharmacol. 2003 Apr;51(4):311-20. doi: 10.1007/s00280-002-0552-1. Epub 2003 Mar 28. Cancer Chemother Pharmacol. 2003. PMID: 12721759
-
Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.ScientificWorldJournal. 2015;2015:751703. doi: 10.1155/2015/751703. Epub 2015 Jun 21. ScientificWorldJournal. 2015. PMID: 26185782 Free PMC article.
-
High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.Pediatr Blood Cancer. 2004 Jul;43(1):17-22. doi: 10.1002/pbc.20032. Pediatr Blood Cancer. 2004. PMID: 15170885 Clinical Trial.
-
Urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate.J Clin Oncol. 1987 May;5(5):804-10. doi: 10.1200/JCO.1987.5.5.804. J Clin Oncol. 1987. PMID: 3471866
-
Use of serum creatinine concentrations to determine renal function.Clin Pharmacokinet. 1979 May-Jun;4(3):200-22. doi: 10.2165/00003088-197904030-00003. Clin Pharmacokinet. 1979. PMID: 383355 Review.
Cited by
-
Clinical pharmacokinetics of commonly used anticancer drugs.Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002. Clin Pharmacokinet. 1983. PMID: 6189661 Review.
-
Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.Cancer Chemother Pharmacol. 1982 Dec;10(1):36-9. doi: 10.1007/BF00257235. Cancer Chemother Pharmacol. 1982. PMID: 6961972
-
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data.Cancer Chemother Pharmacol. 1994;33(6):493-6. doi: 10.1007/BF00686507. Cancer Chemother Pharmacol. 1994. PMID: 8137460
-
Cancer chemotherapy in older adults. A tolerability perspective.Drugs Aging. 1997 Jan;10(1):34-49. doi: 10.2165/00002512-199710010-00004. Drugs Aging. 1997. PMID: 9111706 Review.
-
Concentration and pH dependent steady-state volume of distribution of methotrexate estimated by a simple physiologically based method.J Pharmacokinet Biopharm. 1984 Dec;12(6):597-610. doi: 10.1007/BF01059555. J Pharmacokinet Biopharm. 1984. PMID: 6533295
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources